Brief: Astria Therapeutics Presents Data Supporting STAR-0215 Profile For Hereditary Angioedema

Astria Therapeutics

24/02/2023 13:05

Feb 24 (Reuters) - Astria Therapeutics Inc  ATXS.O :
    * ASTRIA THERAPEUTICS PRESENTS ADDITIONAL DATA SUPPORTING
STAR-0215 PROFILE AS A LONG-ACTING PREVENTATIVE THERAPY FOR
HEREDITARY ANGIOEDEMA AT THE 2023 AMERICAN ACADEMY OF ALLERGY,
ASTHMA, AND IMMUNOLOGY ANNUAL MEETING
    * ASTRIA THERAPEUTICS - ADDITIONAL PHASE 1A DATA SHOWS
STAR-0215
HAS ESTIMATED HALF-LIFE OF UP TO 117 DAYS
    * ASTRIA THERAPEUTICS INC -  ADDITIONAL PHASE 1A CLINICAL
DATA
SUPPORTING POTENTIAL FOR DOSING ONCE EVERY THREE MONTHS OR LESS
FREQUENTLY
    * ASTRIA THERAPEUTICS INC - STAR-0215 DIFFERENTIATED PLASMA
KALLIKREIN BINDING IS CONSISTENT WITH HIGH SPECIFICITY

Source text for Eikon:  ID:nBw5Wc2Jta 
Further company coverage:  ATXS.O 
 ((Reuters.Briefs@thomsonreuters.com;))